Article List

WPRIM Management System> DCMS> Chinese Journal of Cardiology> 2006> 34> 10

Volume: 34 Issue: 10

1. Real-time three-dimensional echocardiography: imaging method, research status and its future.	Page:951—955
2. Advancement in pharmacogenomics of beta-blocker therapy.	Page:947—950
3. The protective effect of PEP-1-CAT fusion protein on hydrogen peroxide-induced oxidative stress injury in human umbilical vein endothelial cells.	Page:932—938
4. Porcine MSC-derived CLC induced by rabbit's cardiomyocytes extract did not induce immune reaction in vivo.	Page:929—931
5. Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor.	Page:922—928
6. Pacemaker current gene expression of rat mesenchymal stem cells and identification of mesenchymal stem cells expressing human pacemaker current gene (hHCN2).	Page:917—921
7. Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway.	Page:912—916
8. Blood pressure changes post liver transplantation in 206 recipients.	Page:902—904
9. The hemodynamic effect of dobutamine stress on myocardial bridging-mural coronary artery.	Page:899—901
10. Chronotropic incompetence predicts angiographic severity in patients with coronary artery disease.	Page:895—898
11. The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial.	Page:890—894
12. The beneficial effects of xuezhikang on top of extended-released nifedipine in hypertensive patients without severe hyperlipidemia.	Page:886—889
13. The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia.	Page:882—885
14. Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension.	Page:877—881
15. Aldosterone/plasma renin activity ratio is a sensitive parameter for screening patients with primary aldosteronism.	Page:873—876
16. Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients.	Page:868—872
17. New concepts in searching for primary aldosteronism in hypertension: advances in screening, confirming and subtyping tests.	Page:865—867